MedTrace Logo

MyoVista wavECG Clinical Evaluation: >=60 y/o Enrichment Population

NCT05364541 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-09-21

No results posted yet for this study

Summary

This is a single-center, interventional, single arm clinical study of the MyoVista wavECG for the detection of LV relaxation abnormalities. The study will be conducted at a single investigational site within the United States. Study subjects will predominately be screened from among those who have been enrolled in prior registry studies by the institution.

Conditions

  • Health Screening

Interventions

DEVICE

MyoVista wavECG

A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.

Sponsors & Collaborators

  • Heart Test Laboratories, Inc.

    lead INDUSTRY

Principal Investigators

  • Partho Sengupta, MD · Rutgers Robert Wood Johnson Medical School

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-07-15
Completion
2023-11-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05364541 on ClinicalTrials.gov